Article

Positive Trial Results for Blood Thinner

Author(s):

AstraZeneca announced that its study of ticagrelor (Brilinta) has met its primary efficacy endpoint. In the trial known as Pegasus-TIMI 54, some 21,000 patients taking the tablets twice a day at a dose of either 60 mg or 90 mg plus low-dose aspirin for secondary prevention experienced no unexpected safety issues.

AstraZeneca announced that its study of ticagrelor (Brilinta) has met its primary efficacy endpoint. In the trial known as Pegasus-TIMI 54, some 21,000 patients taking the tablets twice a day at a dose of either 60 mg or 90 mg plus low-dose aspirin for secondary prevention experienced no unexpected safety issues.

Complete results will be presented in March at the American College of Cardiology meeting in San Diego, CA.

According to Tim Anderson, a financial analyst with Sanford Bernstein, the drug—if approved for secondary prevention—faces competition from Plavix.

Plavix may already have a lead since “Plavix already gets used off-label to a moderate degree” in heart attack patients similar to the patient population in the Pegasus trial.

Plavix was one of the drugs used in recent dual anti-platelet therapy trials, the subject of several papers at the November 2014 ACC meeting in Chicago.

Doctors disagree on whether dual anti-platelet therapy should be continued past one year, due to the increased risk of bleeding in such therapy. US physicians seem more receptive to the idea than do European doctors.

According to AstraZeneca, the patients in the Pegasus trial represent only a fraction of the overall market for such a product.

Related Videos
The APAC Recap: Cardiomyopathy at CAPP Live 2024 with Greg Duck, PA-C | Image Credit: APAC
The APAC Recap: Peripheral Artery Disease at CAPP Live 2024 with Bob Ross, PA-C | Image Credit: APAC
AMG0001 Advances Healing in CLTI with David G. Armstrong, DPM, PhD, and Michael S. Conte, MD | Image Credit: Canva
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
© 2024 MJH Life Sciences

All rights reserved.